DE69131292D1 - Antikoagulierende proteine - Google Patents

Antikoagulierende proteine

Info

Publication number
DE69131292D1
DE69131292D1 DE69131292T DE69131292T DE69131292D1 DE 69131292 D1 DE69131292 D1 DE 69131292D1 DE 69131292 T DE69131292 T DE 69131292T DE 69131292 T DE69131292 T DE 69131292T DE 69131292 D1 DE69131292 D1 DE 69131292D1
Authority
DE
Germany
Prior art keywords
factor vii
modified
wild
coagulation cascade
anticoagulant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69131292T
Other languages
English (en)
Other versions
DE69131292T2 (de
Inventor
Kathleen Berkner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of DE69131292D1 publication Critical patent/DE69131292D1/de
Application granted granted Critical
Publication of DE69131292T2 publication Critical patent/DE69131292T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69131292T 1990-01-29 1991-01-25 Antikoagulierende proteine Expired - Fee Related DE69131292T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47131390A 1990-01-29 1990-01-29
PCT/US1991/000552 WO1991011514A1 (en) 1990-01-29 1991-01-25 Anticoagulant proteins

Publications (2)

Publication Number Publication Date
DE69131292D1 true DE69131292D1 (de) 1999-07-08
DE69131292T2 DE69131292T2 (de) 1999-09-30

Family

ID=23871126

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69131292T Expired - Fee Related DE69131292T2 (de) 1990-01-29 1991-01-25 Antikoagulierende proteine

Country Status (8)

Country Link
US (2) US5288629A (de)
EP (1) EP0521873B1 (de)
JP (2) JP3330932B2 (de)
AT (1) ATE180834T1 (de)
AU (1) AU651573B2 (de)
CA (1) CA2074839C (de)
DE (1) DE69131292T2 (de)
WO (1) WO1991011514A1 (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
JPH05506361A (ja) * 1990-05-17 1993-09-22 ダナ―ファーバー　キャンサー　インスティテュート　インク 多量体蛋白質に対するトランス―ドミナントサプレッサ遺伝子
US6475781B1 (en) 1990-05-17 2002-11-05 Dana-Farber Cancer Institute, Inc. Trans-dominant suppressor genes for oligomeric proteins
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
HU218890B (hu) * 1991-02-28 2000-12-28 Novo Nordisk A/S Véralvadást gátló módosított VII faktorok, ezeket kódoló polinukleotid molekulák, polinukleotid molekulával transzfektált emlős sejtek és a véralvadást gátló módosított VII faktorokat tartalmazó gyógyászati készítmények, valamint a készítmények ...
US5833982A (en) * 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US20040087498A1 (en) * 1991-02-28 2004-05-06 Novo Nordisk Health Care Ag Modified factor VII
US5861374A (en) * 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US6039944A (en) * 1992-02-28 2000-03-21 Zymogenetics, Inc. Modified Factor VII
PT699075E (pt) * 1993-05-21 2002-05-31 Novo Nordisk As Factor vii modificado para inibicao de restenose vascular e de deposicao de plaquetas
WO1994028017A1 (en) * 1993-06-01 1994-12-08 The Scripps Research Institute Human mutant tissue factor compositions useful as tissue factor antagonists
HUT74873A (en) * 1993-06-18 1997-02-28 Nycomed Imaging As Factor vii-derived peptides
US5510248A (en) * 1993-06-22 1996-04-23 The University Of British Columbia Stable recombinant meizothrombin-like polypeptides
US6017882A (en) * 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) * 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
AR017831A1 (es) 1997-12-10 2001-10-24 Pioneer Hi Bred Int Metodo para alterar la composicion de aminoacidos de una proteina nativa de interes, proteina elaborada, y polinucleotido
US6924359B1 (en) 1999-07-01 2005-08-02 Yale University Neovascular-targeted immunoconjugates
WO2001001749A2 (en) 1999-07-02 2001-01-11 Genentech, Inc. FVIIa ANTAGONISTS
US6586574B1 (en) * 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
PT1257295E (pt) 2000-02-11 2009-07-16 Bayer Healthcare Llc Moléculas de tipo factor vii ou viia
WO2001070763A1 (en) * 2000-03-22 2001-09-27 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6905683B2 (en) * 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US7160540B2 (en) * 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
EP2226385B1 (de) 2000-09-13 2013-07-10 Novo Nordisk Health Care AG Varianten des menschlichen Koagulationsfaktors VII
ES2429523T3 (es) 2000-09-13 2013-11-15 Novo Nordisk Health Care Ag Variantes del factor VII de coagulación humana
WO2002055110A2 (en) * 2000-10-25 2002-07-18 Genzyme Corp Methods for treating blood coagulation disorders
WO2002038162A1 (en) * 2000-11-09 2002-05-16 The Scripps Research Institute MODIFIED FACTOR VIIa
EP1373493B1 (de) 2001-03-22 2013-07-31 Novo Nordisk Health Care AG Derivat des koagulationsfaktors vii
HUP0500060A3 (en) 2001-09-27 2010-01-28 Novo Nordisk Healthcare Ag Human coagulation factor vii polypeptides
US7052868B2 (en) * 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US8008252B2 (en) * 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US6960657B2 (en) * 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
ATE428439T1 (de) 2001-12-21 2009-05-15 Novo Nordisk Healthcare Ag Flüssige zusammensetzung aus faktor vii polypeptiden
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
US7164002B2 (en) 2002-02-06 2007-01-16 Genentech, Inc. FVIIa antagonists
CN1665925A (zh) * 2002-04-30 2005-09-07 马克西根控股公司 凝血因子Ⅶ或Ⅶa多肽变体
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
PT1517698E (pt) 2002-06-21 2014-11-19 Novo Nordisk Healthcare Ag Composições sólidas estabilizadas de polipéptidos do fator viia
DE60336555D1 (de) * 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
US6911323B2 (en) * 2002-09-25 2005-06-28 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
CA2502162C (en) * 2002-09-30 2014-04-15 Maxygen Holdings Ltd. Fvii or fviia variants having increased clotting activity
US20040176704A1 (en) * 2003-03-04 2004-09-09 Stevens Timothy A Collection device adapted to accept cartridge for point of care system
AU2004221758B2 (en) 2003-03-18 2010-07-22 Novo Nordisk Health Care Ag Method for the production of GLA-residue containing serine proteases
BRPI0408439A (pt) * 2003-03-18 2006-04-04 Novo Nordisk Healthcare Ag composição farmacêutica lìquida aquosa, método para preparar e uso da mesma, método para tratar uma sìndrome responsiva ao fator vii, e, recipiente hermético
ATE431403T1 (de) 2003-03-20 2009-05-15 Bayer Healthcare Llc Fvii oder fviia varianten
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
MXPA05012476A (es) * 2003-05-23 2006-02-22 Novo Nordisk Healthcare Ag Estabilizacion de proteina en solucion.
NZ544728A (en) 2003-06-19 2009-04-30 Bayer Healthcare Llc Factor VII or VIIa Gla domain variants
DE602004023848D1 (de) * 2003-07-01 2009-12-10 Novo Nordisk Healthcare Ag Von factor vii polypeptiden
JP5653572B2 (ja) 2003-08-14 2015-01-14 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液状水性医薬組成物
ES2381110T3 (es) 2003-09-09 2012-05-23 Novo Nordisk Health Care Ag Polipéptidos de factor VII de coagulación
US20080193441A1 (en) * 2003-11-18 2008-08-14 Iconic Therapeutics, Inc. Homogeneous Preparations of Chimeric Protein
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
WO2005058283A2 (en) * 2003-12-19 2005-06-30 Novo Nordisk Health Care Ag Stabilised compositions of factor vii polypeptides
JP2007522805A (ja) * 2004-02-03 2007-08-16 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 新規化合物
EP2975135A1 (de) 2005-05-25 2016-01-20 Novo Nordisk A/S Glykopegylierter Faktor IX
EP1926817A2 (de) 2005-09-14 2008-06-04 Novo Nordisk Health Care AG Menschliche gerinnungsfaktor-vii-polypeptide
EP1929005A1 (de) * 2005-09-21 2008-06-11 Novo Nordisk Health Care AG Menschliche gerinnungsfaktor-vii-polypeptide
WO2007104317A1 (en) * 2006-03-16 2007-09-20 Drugrecure Aps Methods for local treatment with factor vii
JP5122562B2 (ja) * 2006-07-17 2013-01-16 ノボ ノルディスク ヘルス ケア アーゲー 増加した活性を有する第ｖｉｉａ因子アナログの新規用途
US20100166729A9 (en) * 2007-04-13 2010-07-01 Madison Edwin L Modified factor VII polypeptides and uses thereof
US9493499B2 (en) 2007-06-12 2016-11-15 Novo Nordisk A/S Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
TWI538916B (zh) 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
DK2440239T3 (en) 2009-06-09 2017-10-16 Prolong Pharmaceuticals Llc HEMOGLOBIN FORMATIONS
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
CN114728044A (zh) 2019-08-15 2022-07-08 介控生化科技公司 用于皮下施用和按需求治疗的经修饰的因子vii多肽

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
WO1986006408A1 (en) * 1985-04-22 1986-11-06 Genetics Institute, Inc. HIGH YIElD PRODUCTION OF ACTIVE FACTOR IX
US4959318A (en) * 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
US5258288A (en) * 1986-07-25 1993-11-02 Genzyme Corporation Vector containing DNA encoding mature human protein S
DK323587D0 (da) * 1987-06-25 1987-06-25 Novo Industri As Protein
FI882746A (fi) * 1987-06-12 1988-12-13 Hoechst Japan Hybridprotein c och foerfarande foer dess framstaellning.
US4994371A (en) * 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5023236A (en) * 1988-04-07 1991-06-11 Corvas, Inc. Factor VII/VIIA active site inhibitors

Also Published As

Publication number Publication date
US5824639A (en) 1998-10-20
AU651573B2 (en) 1994-07-28
ATE180834T1 (de) 1999-06-15
US5288629A (en) 1994-02-22
JP3330932B2 (ja) 2002-10-07
CA2074839A1 (en) 1991-07-30
EP0521873B1 (de) 1999-06-02
EP0521873A1 (de) 1993-01-13
WO1991011514A1 (en) 1991-08-08
DE69131292T2 (de) 1999-09-30
CA2074839C (en) 2000-11-14
JP2002247996A (ja) 2002-09-03
JPH05500161A (ja) 1993-01-21
AU7300291A (en) 1991-08-21
EP0521873A4 (en) 1993-05-05

Similar Documents

Publication Publication Date Title
DE69131292D1 (de) Antikoagulierende proteine
Elg et al. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor
CA1244763A (en) Blood coagulation inhibiting proteins, processes for preparing them and their uses
JP5037331B2 (ja) 出血性障害の処置のための第ｉｘａ因子
US5453373A (en) Protein C derivatives
Elg et al. Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits
Bajwa et al. Thrombin-like and fibrinolytic enzymes in the venoms from the Gaboon viper (Bitis gabonica), eastern cottonmouth moccasin (Agkistrodon p. piscivorus) and southern copperhead (Agkistrodon c. contortrix) snakes
AU3050384A (en) Removal of lipid containing virus in blood
CA2060507A1 (en) Factor xa based anticoagulant compositions
Blombäck et al. Fibrinolytics and antifibrinolytics
Gitel et al. The antithrombotic effects of warfarin and heparin following infusions of tissue thromboplastin in rabbits: clinical implications
Vinazzer Clinical use of antithrombin III concentrates
US5922358A (en) Antithrombotic and non-hemorrhagic heparin-based compositions, process for their preparation and therapeutic applications
Aronson Factor IX complex
US5637299A (en) Enhancement of thrombolytic therapy with deglycosylated forms of plasminogen
Nagaki et al. Inactivator of the First Component of Human Complement (CĪINA) Enhancement of CĪlNA Activity against CĪs by Acidic Mucopolysaccharides
US20110053851A1 (en) Haemostasis-modulating compositions and uses therefor
Pechet et al. The effect of certain proteolytic enzymes on the thrombin-fibrinogen interaction
Bara et al. Increased anti-Xa bioavailability for a low molecular weight heparin (PK 10169) compared with unfractionated heparin
Grotto et al. Effect of purified Vipera palestinae hemorrhagin on blood coagulation and platelet function
Weinstein et al. Enhancement of rabbit protein S anticoagulant cofactor activity in vivo by modulation of the protein S C4B binding protein interaction.
Prentice et al. Studies on the anticoagulant action of aprotinin (“Trasylol”)
Seegers et al. Autocatalysis in prothrombin activation
Pejler Procoagulant and anticoagulant activities of resident and inflammatory peritoneal cells
JPH07291999A (ja) 血小板安定化因子ｉｘ−フラグメント、その製造方法及びこれを含有する薬剤

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: VONNEMANN, KLOIBER & KOLLEGEN, 80796 MUENCHEN

8339 Ceased/non-payment of the annual fee